Multispecific Antibody Development Platform

Multispecific Antibody Development Platform Overview

multispecific antibody development platform service

Our proprietary platforms, the KY-CLC-mouseTM (common light chain gene-edited mice) and KY-HC-mouseTM (heavy-chain only gene-edited mice), enable the discovery of bispecific antibodies and nanobodies to support the development of next-generation multi-specific antibody drugs. The KY-CLC-mouseTM has an identical κ light chain without expression of λ light chain. This common κ light chain was modified from a light chain frequently appearing in mice and paired with different heavy chains. The KY-HC-mouseTM produces heavy-chain-only IgGs with broad diversity and high affinities to antigens. A heavy-chain antibody consists of two heavy chains without the light chain usually found in regular antibodies, and nanobodies were derived from heavy-chain-only antibodies.

Technology

Genetically engineered cell lines

Genetically engineered cell lines revolutionize research, enabling precise studies on diseases, therapies, and biological processes for innovative medical advancements.

In vitro and in vivo pharmacology

In vitro pharmacology explores drug effects in controlled lab settings, while in vivo studies investigate drug responses within living organisms.

Bispecific and tri-specific antibody discovery platform

Revolutionize immunotherapy with our cutting-edge Bispecific and Tri-specific Antibody Discovery Platform, enhancing precision and efficacy in targeted cancer treatments

MPSA-AB5000 panel

Genetically engineered cell lines revolutionize research, enabling precise studies on diseases, therapies, and biological processes for innovative medical advancements.

AI-based antibody development platform

Revolutionize immunotherapy with our cutting-edge Bispecific and Tri-specific Antibody Discovery Platform, enhancing precision and efficacy in targeted cancer treatments